

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 26 (Cancelled)

Claim 27. (Currently amended) A solid oral pharmaceutical composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or a pharmaceutically acceptable salt thereof ~~an acid sensitive agent~~ and a disintegrant which is present in an amount of at least 15% by weight based on the total weight of the composition, wherein the disintegrant is a member selected from the group consisting of crospovidone, sodium starch glycolate, carboxymethylcellulose sodium, sodium alginate, and a mixture thereof.

Claims 28 – 34 (Cancelled)

Claim 35. (Previously presented) A solid oral pharmaceutical composition according to claim 34 wherein the disintegrant is crospovidone.

Claim 36. (Currently amended) A solid oral pharmaceutical composition according to claim 27 ~~35~~ further comprising a lubricant.

Claim 37. (Previously presented) A solid oral pharmaceutical composition according to claim 36 wherein the lubricant comprises a glyceryl mono fatty acid.

Claim 38. (Previously presented) A solid oral pharmaceutical composition according to claim 36 wherein the lubricant comprises a mixture of glyceryl monostearate and polyethylene glycol.

Claim 39. (Previously presented) A solid oral pharmaceutical composition according to claim 38 further comprising a surfactant.

Claim 40. (Previously presented) A solid oral pharmaceutical composition according to claim 39 wherein the surfactant is a member selected from the group consisting of a polyoxytheylene-sorbitan-fatty acid ester, a polyoxyethylene fatty acid ester, a polyoxyethylene-polyoxypropylene block co-polymer, a reaction product of a natural or hydrogenated castor oil and ethylene oxide, dioctylsuccinate, di-[2-ethylhexyl]-succinate, a propylene glycol mono-fatty acid, and a propylene glycol di-fatty acid.

Claim 41. (Previously presented) A solid oral pharmaceutical composition according to claim 40 wherein the surfactant comprises a polyoxyethylene-polyoxypropylene block co-polymer.

Claim 42. (Previously presented) A solid oral pharmaceutical composition according to claim 41 further comprising lactose and hydroxypropylmethylcellulose.

Claim 43. (Currently amended) A solid oral pharmaceutical composition of claim 27 ~~35~~, wherein said pharmaceutical composition has dissolution characteristics in water or USP buffers pH 6.8 and 7.5 of:

time (minutes)	amount (percentage)
5	30 - 90
15	80 - 100
30	95 - 100
60	100.

Claim 44. (Currently amended) A solid oral pharmaceutical composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or a pharmaceutically acceptable salt thereof ~~an acid sensitive agent~~ and a disintegrant which is present in an amount between 20% and 60% by weight based on the total weight of the composition, wherein the disintegrant is carboxymethylcellulose calcium.

Claim 45. (Currently amended) A solid oral pharmaceutical composition according to claim 44 wherein the pharmaceutically acceptable salt ~~acid sensitive agent~~ is the ~~a~~ maleate salt of 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide.

Claim 46. (Currently amended) A solid oral pharmaceutical composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or a pharmaceutically acceptable salt thereof ~~an acid sensitive agent~~ and a disintegrant which is present in an amount between 30% and 50% by weight based on the total weight of the composition, wherein the disintegrant is pregelatinized starch.

Claim 47. (Currently amended) A solid oral pharmaceutical composition according to claim 46 wherein the pharmaceutically acceptable salt ~~the acid sensitive agent~~ is the ~~a~~ maleate salt of 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide.

Claim 48. (Previously presented) A solid oral pharmaceutical composition according to claim 27 wherein said composition is a tablet.

Claim 49. (Cancelled)

Claim 50. (Previously presented) A solid oral pharmaceutical composition according to claim 35 wherein said composition is a tablet.

Claim 51. (Previously presented) A solid oral pharmaceutical composition according to claim 45 wherein said composition is a tablet.

Claim 52. (Previously presented) A solid oral pharmaceutical composition according to claim 47 wherein said composition is a tablet.